|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
|
WO1995001997A1
(fr)
|
1993-07-09 |
1995-01-19 |
Smithkline Beecham Corporation |
ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US5759546A
(en)
|
1994-02-04 |
1998-06-02 |
Weinberg; Andrew D. |
Treatment of CD4 T-cell mediated conditions
|
|
US6242566B1
(en)
|
1994-02-10 |
2001-06-05 |
Board Of Trustees Of The Leland Stanford Junior University |
Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
|
|
ATE279947T1
(de)
|
1996-03-18 |
2004-11-15 |
Univ Texas |
Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
|
|
WO1998023289A1
(fr)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
Modulation de la fixation de l'igg au fcrn
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
AU2873999A
(en)
|
1998-02-24 |
1999-09-06 |
Sisters Of Providence In Oregon |
Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
|
|
HRP20130077A2
(hr)
|
1998-12-23 |
2013-07-31 |
Pfizer Inc. |
Humana monoklonalna protutjela za ctla-4
|
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US20030035790A1
(en)
|
1999-01-15 |
2003-02-20 |
Shu-Hsia Chen |
Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
|
|
CN102766210B
(zh)
|
1999-08-24 |
2015-07-08 |
E.R.施贵宝&圣斯有限责任公司 |
人ctla-4抗体及其应用
|
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
|
CA2423436A1
(fr)
|
2000-10-02 |
2002-04-11 |
Anthony Montgomery |
Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations
|
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン，エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20150329617A1
(en)
|
2001-03-14 |
2015-11-19 |
Dynal Biotech Asa |
Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
|
|
JP2005511627A
(ja)
|
2001-11-20 |
2005-04-28 |
シアトル ジェネティクス，インコーポレーテッド |
抗ｃｄ３０抗体を使用する免疫学的疾患の治療
|
|
TW200303759A
(en)
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
|
AU2002365814A1
(en)
|
2001-12-18 |
2003-07-30 |
J And J Research Pty Ltd |
Method of treating asthma
|
|
AUPS054702A0
(en)
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
|
JP2005528373A
(ja)
|
2002-03-26 |
2005-09-22 |
イミュネックス・コーポレーション |
免疫プロトコルにＦｌｔ３リガンドを用いる方法
|
|
PE20040079A1
(es)
|
2002-04-03 |
2004-04-19 |
Novartis Ag |
Derivados de indolilmaleimida
|
|
US20030223989A1
(en)
|
2002-04-18 |
2003-12-04 |
Pluenneke John D. |
CD137 agonists to treat patients with IgE-mediated conditions
|
|
NZ536746A
(en)
|
2002-06-13 |
2007-02-23 |
Crucell Holland Bv |
An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
|
|
CA2493081C
(fr)
|
2002-07-12 |
2013-04-23 |
The Johns Hopkins University |
Reactifs et procedes permettant d'impliquer des recepteurs clonotypiques de lymphocytes uniques
|
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
CA2503457A1
(fr)
|
2002-10-25 |
2004-05-06 |
University Of Connecticut Health Center |
Appareil et methode d'immunotherapie d'un cancer par lyse cellulaire commandee
|
|
DE10261223A1
(de)
|
2002-12-20 |
2004-07-08 |
MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH |
Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
|
|
EP2572714A1
(fr)
|
2002-12-30 |
2013-03-27 |
3M Innovative Properties Company |
Combinaisons immunostimulantes
|
|
GB0303319D0
(en)
|
2003-02-13 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
GB0303663D0
(en)
|
2003-02-18 |
2003-03-19 |
Lorantis Ltd |
Assays and medical treatments
|
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
US7402431B2
(en)
|
2004-03-01 |
2008-07-22 |
Immunovative Therapies, Ltd. |
T-cell therapy formulation
|
|
US7435592B2
(en)
|
2003-05-13 |
2008-10-14 |
Immunovative Therapies, Ltd. |
Compositions for allogeneic cell therapy
|
|
AU2004242846A1
(en)
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
|
|
US20070010450A1
(en)
|
2003-06-13 |
2007-01-11 |
Microbia, Inc., A Massachusetts Corporation |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
WO2005049085A1
(fr)
|
2003-11-18 |
2005-06-02 |
Valeocyte Therapies Llc |
Utilisation de complexes solubles pour faciliter l'activation cellulaire
|
|
CA2552740A1
(fr)
|
2004-01-19 |
2005-07-28 |
Novartis Ag |
Derives indolylmaleimide utilises en tant qu'inhibiteurs de la pkc
|
|
US7592431B2
(en)
|
2004-02-26 |
2009-09-22 |
Immunovative Therapies, Ltd. |
Biodegradable T-cell Activation device
|
|
AU2005249396B2
(en)
|
2004-05-05 |
2011-10-20 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
|
US7323235B2
(en)
|
2004-07-20 |
2008-01-29 |
Graham Group, Inc. |
Multi-strip promotional piece
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
ES2605380T3
(es)
|
2005-05-06 |
2017-03-14 |
Providence Health & Services - Oregon |
Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
|
|
GB0512225D0
(en)
|
2005-06-16 |
2005-07-27 |
Univ Sheffield |
Immunoglobulin molecules
|
|
JP2006345852A
(ja)
|
2005-06-16 |
2006-12-28 |
Virxsys Corp |
抗体複合体
|
|
WO2007016340A2
(fr)
|
2005-07-29 |
2007-02-08 |
Providence Health System |
Produits de ribosome défectueux dans les blebs (flux salivaires inconscients) et procédés d’utilisation pour stimuler une réponse immunitaire
|
|
EP1941275B1
(fr)
|
2005-09-29 |
2013-07-24 |
Medimmune, Inc. |
Méthode d'identification d'anticorps spécifiques de membranes longueur d'onde et leurs utilisations pour cibler les cellules précurseurs productrices d'immunoglobuline
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
US7812133B2
(en)
|
2005-12-16 |
2010-10-12 |
Genentech, Inc |
Anti-OX40L antibodies and methods using same
|
|
US20110008368A1
(en)
|
2006-01-13 |
2011-01-13 |
Board Of Regents, The University Of Texas System |
Methods of modulating the ox40 receptor to treat cancer
|
|
US20080286286A1
(en)
|
2006-01-13 |
2008-11-20 |
Board Of Regents, The University Of Texas System |
Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor
|
|
WO2007133822A1
(fr)
|
2006-01-19 |
2007-11-22 |
Genzyme Corporation |
Anticorps anti-gitr destinés au traitement du cancer
|
|
WO2007111931A2
(fr)
|
2006-03-22 |
2007-10-04 |
Imperial Innovations Limited |
Compositions et procédés en relation avec la modulation de composantes du système immunitaire
|
|
WO2007130555A2
(fr)
|
2006-05-02 |
2007-11-15 |
Providence Health System |
Augmentation de la réaction immunitaire au vaccin contre le cancer
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
US10106619B2
(en)
|
2006-10-04 |
2018-10-23 |
La Jolla Institute For Allergy And Immunology |
Virus vaccination and treatment methods with OX40 agonist compositions
|
|
EP1914242A1
(fr)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
US20100136030A1
(en)
|
2007-02-27 |
2010-06-03 |
Lamhamedi-Cherradi Salah-Eddine |
Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
|
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
RU2010113510A
(ru)
|
2007-09-07 |
2011-10-20 |
Симфоген А/С (Dk) |
Способы рекомбинантной продукции антител против респираторно-цинцитиального вируса (rsv)
|
|
EP2192922A4
(fr)
|
2007-09-17 |
2010-09-29 |
Univ California |
Anticorps monoclonaux humains internalisants ciblant des cellules du cancer de la prostate<i>in situ</i>
|
|
KR101577843B1
(ko)
|
2007-12-14 |
2015-12-16 |
브리스톨-마이어스 스큅 컴퍼니 |
인간 ｏｘ４０ 수용체에 대한 결합 분자
|
|
US8263073B2
(en)
|
2008-02-04 |
2012-09-11 |
Medarex, Inc. |
Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
|
|
WO2009141239A1
(fr)
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
Formulation pharmaceutique comprenant un anticorps contre ox40l, utilisations de celle-ci
|
|
ES2524266T3
(es)
|
2008-07-08 |
2014-12-04 |
Incyte Corporation |
1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
|
|
US20110318380A1
(en)
|
2008-10-01 |
2011-12-29 |
Dako Denmark A/S |
MHC Multimers in Cancer Vaccines and Immune Monitoring
|
|
WO2010054007A1
(fr)
*
|
2008-11-07 |
2010-05-14 |
Fabrus Llc |
Bibliothèques combinatoires d'anticorps et leurs utilisations
|
|
CN102272158B
(zh)
|
2008-11-12 |
2014-05-07 |
乔治·K·刘易斯 |
源自记忆b细胞的人单克隆抗体的快速表达克隆
|
|
BRPI1008692B8
(pt)
|
2009-02-17 |
2021-05-25 |
Ucb Biopharma Sprl |
anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
|
|
US20120070450A1
(en)
|
2009-03-24 |
2012-03-22 |
Riken |
Leukemia stem cell markers
|
|
PT3023438T
(pt)
*
|
2009-09-03 |
2020-05-08 |
Merck Sharp & Dohme |
Anticorpos anti-gitr
|
|
CA2781311C
(fr)
|
2009-12-07 |
2019-03-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methodes d'amplification d'un traitement a base d'anticorps anticancereux
|
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
PT2542590T
(pt)
|
2010-03-05 |
2017-08-31 |
Univ Johns Hopkins |
Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
|
|
GB201006096D0
(en)
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
|
US20110256184A1
(en)
|
2010-04-14 |
2011-10-20 |
Battelle Memorial Institute |
Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release
|
|
EP2399604A1
(fr)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Nouvelle formulation d'anticorps
|
|
WO2012012518A2
(fr)
|
2010-07-20 |
2012-01-26 |
University Of Miami |
Inhibition des voies de dégradation des arnm non-sens
|
|
WO2012027328A2
(fr)
|
2010-08-23 |
2012-03-01 |
Board Of Regents, The University Of Texas System |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
EP2637691A4
(fr)
|
2010-11-08 |
2015-09-02 |
Biovest Int Inc |
Matériels et méthodes pour l'orientation d'une réponse immunitaire vers un épitope
|
|
DK2663580T3
(en)
|
2011-01-10 |
2017-03-13 |
Ct Atlantic Ltd |
COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
US9409987B2
(en)
|
2011-04-15 |
2016-08-09 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
EP2714743A1
(fr)
|
2011-06-03 |
2014-04-09 |
CT Atlantic Ltd. |
Anticorps se liant à mage a3
|
|
AU2012273182A1
(en)
|
2011-06-21 |
2014-01-16 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
|
HRP20180858T1
(hr)
*
|
2011-07-11 |
2018-09-21 |
Glenmark Pharmaceuticals S.A. |
Protutijela koja se vežu na ox40 i njihove uporabe
|
|
US9701749B2
(en)
|
2011-08-11 |
2017-07-11 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising PD-1 agonist
|
|
KR101685262B1
(ko)
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ｏｘ４０ 항체 및 이의 사용 방법
|
|
US8920075B2
(en)
|
2011-09-01 |
2014-12-30 |
Halo Maritime Defense Systems, Inc. |
Marine barrier and gate
|
|
WO2013039954A1
(fr)
*
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anticorps anti-gitr
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
WO2013049307A2
(fr)
|
2011-09-30 |
2013-04-04 |
University Of Miami |
Développement d'une mémoire immunitaire améliorée par une inhibition de mtor des lymphocytes t ciblée par un aptamère
|
|
US9803004B2
(en)
|
2011-11-11 |
2017-10-31 |
Ucb Biopharma Sprl |
Albumin binding antibodies and binding fragments thereof
|
|
UA112203C2
(uk)
*
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
US9365496B2
(en)
|
2011-11-30 |
2016-06-14 |
Ludwig Institute For Cancer Research |
iNKT cell modulators and methods of using the same
|
|
GB201120860D0
(en)
|
2011-12-05 |
2012-01-18 |
Cambridge Entpr Ltd |
Cancer immunotherapy
|
|
JP6441079B2
(ja)
|
2011-12-19 |
2018-12-19 |
シンイミューン ゲーエムベーハー |
二重特異性抗体分子
|
|
DK2806883T3
(da)
|
2012-01-25 |
2019-07-22 |
Dnatrix Inc |
Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
|
|
SG2014008304A
(en)
|
2012-02-01 |
2014-06-27 |
Compugen Ltd |
C10rf32 antibodies, and uses thereof for treatment of cancer
|
|
US9828432B2
(en)
|
2012-02-06 |
2017-11-28 |
Providence Health & Services—Oregon |
Cancer treatment and monitoring methods using OX40 agonists
|
|
ES2640268T3
(es)
|
2012-02-15 |
2017-11-02 |
Novo Nordisk A/S |
Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
|
|
SG11201404769UA
(en)
|
2012-02-22 |
2014-11-27 |
Univ Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
US20150037346A1
(en)
|
2012-02-23 |
2015-02-05 |
Sloan-Kettering Institute For Cancer Research |
Prediction of Responsiveness to Treatment with Immunomodulatory Therapeutics and Method of Monitoring Abscopal Effects During Such Treatment
|
|
AU2012371610A1
(en)
|
2012-03-02 |
2014-10-02 |
Providence Health & Services - Oregon |
Dual OX40 agonist/IL-2 cancer therapy methods
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
US8993614B2
(en)
|
2012-03-15 |
2015-03-31 |
F. Hoffmann-La Roche Ag |
Substituted pyrrolidine-2-carboxamides
|
|
EP2744830A4
(fr)
|
2012-06-21 |
2015-06-17 |
Compugen Ltd |
Anticorps anti-lsr et leurs utilisations pour le traitement du cancer
|
|
ES2723885T3
(es)
*
|
2012-07-19 |
2019-09-03 |
Daiichi Sankyo Co Ltd |
Anticuerpos anti-Siglec-15
|
|
KR20170039774A
(ko)
|
2012-07-30 |
2017-04-11 |
알렉스 와 힌 영 |
종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
|
|
IN2015DN01361A
(fr)
|
2012-08-02 |
2015-07-03 |
Jn Biosciences Llc |
|
|
EP2951199A4
(fr)
|
2013-01-31 |
2016-07-20 |
Univ Jefferson |
Protéines de fusion pour la modulation des lymphocytes t régulateurs et effecteurs
|
|
WO2015116178A1
(fr)
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Protéines de fusion pour la modulation des lymphocytes t régulateurs et effecteurs
|
|
US10533054B2
(en)
|
2013-01-31 |
2020-01-14 |
Thomas Jefferson University |
Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
|
|
WO2014128245A1
(fr)
|
2013-02-21 |
2014-08-28 |
CORAL, Sandra |
Agents d'hypométhylation de l'adn pour thérapie anticancéreuse
|
|
MD20180107A2
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
|
HK1220919A1
(zh)
|
2013-04-05 |
2017-05-19 |
F. Hoffmann-La Roche Ag |
抗il-4抗体和双特异性抗体及其用途
|
|
JP2016534090A
(ja)
|
2013-07-15 |
2016-11-04 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Ｃｄ３８アゴニストの医学的使用
|
|
TWI888366B
(zh)
|
2013-07-16 |
2025-07-01 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
|
|
JP6693872B2
(ja)
*
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス，インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
TW201605896A
(zh)
*
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
US10966998B2
(en)
|
2013-09-05 |
2021-04-06 |
The Johns Hopkins University |
Cancer therapy via a combination of epigenetic modulation and immune modulation
|
|
WO2015063339A1
(fr)
|
2013-11-04 |
2015-05-07 |
Glenmark Pharmaceuticals S.A. |
Production de cellules t reciblant des immunoglobulines héréro-dimériques
|
|
IL292510A
(en)
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
KR20160137946A
(ko)
|
2013-11-22 |
2016-12-02 |
디엔에이트릭스, 인코포레이티드 |
면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스
|
|
WO2015095423A2
(fr)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Polythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
|
|
NZ721908A
(en)
|
2013-12-20 |
2022-12-23 |
Massachusetts Gen Hospital |
Combination therapy with neoantigen vaccine
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
EP4043493A1
(fr)
|
2013-12-24 |
2022-08-17 |
Janssen Pharmaceutica NV |
Anticorps anti-vista et fragments
|
|
ES3040431T3
(en)
|
2014-03-12 |
2025-10-31 |
Yeda Res & Dev |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
ES2754239T3
(es)
|
2014-03-12 |
2020-04-16 |
Curevac Ag |
Combinación de vacunación y agonistas de OX40
|
|
CN107172880B
(zh)
|
2014-03-24 |
2021-09-28 |
癌症研究技术有限公司 |
含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
|
|
WO2015153514A1
(fr)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
|
|
MA40682B1
(fr)
|
2014-03-31 |
2020-01-31 |
Hoffmann La Roche |
Anticorps anti-ox40 et procédés d'utilisation correspondants
|
|
WO2015153857A1
(fr)
|
2014-04-03 |
2015-10-08 |
Georgia Regents Research Institute, Inc. |
Procédés permettant d'améliorer l'efficacité d'une réponse immunitaire dirigée contre les tumeurs
|
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
US20150307620A1
(en)
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
|
EP2939690A1
(fr)
|
2014-04-29 |
2015-11-04 |
Medizinische Hochschule Hannover |
Vaccins
|
|
SG11201609370QA
(en)
|
2014-05-13 |
2016-12-29 |
Chugai Pharmaceutical Co Ltd |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
|
AU2015271709B2
(en)
*
|
2014-06-06 |
2020-11-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
WO2015197874A2
(fr)
|
2014-06-27 |
2015-12-30 |
Apogenix Gmbh |
Combinaison d'inhibition du cd95/cd95l et d'immunothérapie du cancer
|
|
US10449227B2
(en)
|
2014-06-27 |
2019-10-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Conjugates for immunotherapy
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
SG11201700090RA
(en)
|
2014-07-18 |
2017-02-27 |
Advaxis Inc |
Listeria-based immunogenic compositions for eliciting anti-tumor responses
|
|
WO2016025647A1
(fr)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Traitement tumoral synergique avec l'il-2, un anticorps thérapeutique, et un vaccin contre le cancer
|
|
CR20170060A
(es)
|
2014-08-19 |
2017-04-18 |
Merck Sharp & Dohme |
Anticuerpos anti tigit
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
WO2016040882A1
(fr)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Polythérapie par les inhibiteurs de l'egfr
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
RU2017115315A
(ru)
|
2014-10-03 |
2018-11-08 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
WO2016057898A1
(fr)
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Traitement du cancer par agoniste(s) du tlr9 avec des inhibiteurs du point de contrôle
|
|
WO2016059602A2
(fr)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Méthodes de traitement du cancer et compositions associées
|
|
WO2016065330A1
(fr)
|
2014-10-24 |
2016-04-28 |
Aladar Szalay |
Technique d'immunotherapie combinee pour le traitement du cancer
|
|
ES2727154T3
(es)
|
2014-10-24 |
2019-10-14 |
Astrazeneca Ab |
Combinación
|
|
WO2016066634A2
(fr)
|
2014-10-27 |
2016-05-06 |
Ruprecht-Karls-Universität Heidelberg |
Utilisation d'antagonistes du ccr5 en monothérapie ou en polythérapie pour le traitement du cancer
|
|
JP7305300B2
(ja)
|
2014-11-05 |
2023-07-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
併用免疫療法
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
CN106999594B
(zh)
|
2014-11-11 |
2020-08-18 |
免疫医疗有限公司 |
用于治疗瘤形成的治疗组合
|
|
PL3221346T3
(pl)
|
2014-11-21 |
2021-03-08 |
Bristol-Myers Squibb Company |
Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
|
|
JP2018505911A
(ja)
|
2014-12-05 |
2018-03-01 |
イミュネクスト，インコーポレーテッド |
推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
KR102923234B1
(ko)
|
2014-12-19 |
2026-02-04 |
다나-파버 캔서 인스티튜트 인크. |
키메라 항원 수용체 및 이의 사용 방법
|
|
EP3233918A1
(fr)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Polythérapies
|
|
LT3623386T
(lt)
|
2015-01-08 |
2022-08-10 |
BioNTech SE |
Agonistiniai tnf receptorius surišantys agentai
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
EP3268387A4
(fr)
|
2015-03-11 |
2018-10-10 |
Providence Health & Services - Oregon |
Compositions et méthodes pour améliorer l'efficacité de traitement du cancer
|
|
CA2979712C
(fr)
|
2015-03-25 |
2024-01-23 |
The Regents Of The University Of Michigan |
Compositions nanoparticulaires servant a distribuer des biomacromolecules
|
|
WO2016168361A1
(fr)
|
2015-04-14 |
2016-10-20 |
Polynoma, Llc |
Vaccins polyvalents et thérapie de combinaison pour le traitement de mélanome
|
|
MY188749A
(en)
|
2015-04-17 |
2021-12-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of nivolumab and ipilimumab
|
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
|
CA2985816A1
(fr)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Anticorps antagonistes de la superfamille du recepteur du facteur de necrose anti-tumoral
|
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
|
EA035412B1
(ru)
|
2015-05-29 |
2020-06-10 |
Бристол-Майерс Сквибб Компани |
Антитела к ox40 и их применение
|
|
UA125062C2
(uk)
|
2015-10-01 |
2022-01-05 |
Потенза Терапеутікс, Інк. |
Анти-tigit антигензв'язуючі білки і способи їх застосування
|
|
CA3007022A1
(fr)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anticorps anti-gitr et leurs methodes d'utilisation
|
|
WO2017096276A1
(fr)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anticorps anti-gitr et procédés d'utilisation associés
|
|
EP3383914A4
(fr)
|
2015-12-02 |
2019-10-30 |
Agenus Inc. |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
SG10201912984WA
(en)
|
2015-12-02 |
2020-03-30 |
Agenus Inc |
Antibodies and methods of use thereof
|
|
CA3006963A1
(fr)
|
2015-12-03 |
2017-06-08 |
Ludwig Institute For Cancer Research Ltd. |
Anticorps anti-ox40 et leurs procedes d'utilisation
|
|
PT3429618T
(pt)
|
2016-03-16 |
2024-04-02 |
Amal Therapeutics Sa |
Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
|
|
WO2017186928A1
(fr)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Arn codant pour un anticorps
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|